{"disease":{"id":"psoriasis-pso","name":"psoriasis pso"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, hidradenitis suppurativa, atopic dermatitis, and plaque psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":8,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02922192","title":"Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":90360,"lead_sponsor_name":"Biologics & Biosimilars Collective Intelligence Consortium","has_results":false},{"nct_id":"NCT03456206","title":"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":57053,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04614831","title":"A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":4978,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05589298","title":"The Study of Koebner in Patients With Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":3064,"lead_sponsor_name":"Skane University Hospital","has_results":false},{"nct_id":"NCT04433442","title":"Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2324,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03598790","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1353,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT07221890","title":"A Trial of Academic Detailing to Promote Prescribing of Biosimilars","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1325,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT07041112","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Juan Ruano Ruiz","has_results":false},{"nct_id":"NCT06802848","title":"Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chongqing Genrix Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT04950218","title":"Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT05621369","title":"Psorcast Mobile Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sage Bionetworks","has_results":false},{"nct_id":"NCT07017699","title":"A Study to Assess Deucravacitinib Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03726489","title":"Light Treatment Effectiveness (LITE) Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":783,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT05051943","title":"A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response","phase":"","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT03536884","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":743,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT03074656","title":"The Norwegian Drug Monitoring Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT03370133","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":567,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT02346240","title":"Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":559,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT04967508","title":"A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":503,"lead_sponsor_name":"Samsung Bioepis Co., Ltd.","has_results":true},{"nct_id":"NCT06382051","title":"Modifying PEST for Psoriatic Arthritis Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":502,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03412747","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":478,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT07351448","title":"Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine and Its Correlation With Laboratory Indicators","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Shanghai Yueyang Integrated Medicine Hospital","has_results":false},{"nct_id":"NCT02660580","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":443,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":true},{"nct_id":"NCT03410992","title":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":435,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06801821","title":"Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05637515","title":"Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":374,"lead_sponsor_name":"Biocon Biologics Inc.","has_results":true},{"nct_id":"NCT00773734","title":"Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06790940","title":"Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":310,"lead_sponsor_name":"Shanghai Yueyang Integrated Medicine Hospital","has_results":false},{"nct_id":"NCT03816917","title":"Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral","phase":"","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03816345","title":"Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04173039","title":"Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis","phase":"NA","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Association pour la Recherche Clinique et Immunologique","has_results":false},{"nct_id":"NCT04200690","title":"Effectiveness of Interdisciplinary Care Compared to Usual Care in Patients With Immune-Mediated Inflammatory Diseases","phase":"NA","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT01988103","title":"Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01690299","title":"Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05855967","title":"A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04603027","title":"A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"Evelo Biosciences, Inc.","has_results":true},{"nct_id":"NCT04340076","title":"Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT02326298","title":"An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT06666114","title":"Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment","phase":"","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02326272","title":"A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":227,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT04018599","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":false},{"nct_id":"NCT05969223","title":"Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05272150","title":"Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04277832","title":"Evaluating of New Screening Tool for Arthritis* in Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Bezmialem Vakif University","has_results":false},{"nct_id":"NCT06592274","title":"A Phase 2 Study of HB0017 in Psoriasis Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Huabo Biopharm Co., Ltd.","has_results":false},{"nct_id":"NCT00287118","title":"A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT03932110","title":"Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Istanbul Medeniyet University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}